|  |  |
| --- | --- |
|  | **NHS Prescription Services**Bridge House152 Pilgrim StreetNewcastle upon TyneNE1 6SN0845 850 0001 Email:nhsbsa.prescriptionservices@nhsbsa.nhs.ukWebsite:[www.nhsbsa.nhs.uk](http://www.nhsbsa.nhs.uk)  10 June 2024 |
|  |

VERSION 6.1.0

Dear dm+d User,

## [**Share your views - Uplifting SCCI0052: Dictionary of medicines and devices (dm+d)**](https://nhsengland.kahootz.com/t_c_home/viewBlogArticle?articleID=1070105&nextURL=%2Ft_c_home%2FviewBlog%3Fblogid%3D50136)

As part of the [UK Medicines Terminology Futures work](https://digital.nhs.uk/services/terminology-and-classifications/uk-medicines-terminology-futures), we are seeking feedback from those who use or manage dm+d data, to understand the impacts of uplifting SCCI0052 dm+d.

The scope for uplifting the Standard is:​

* ​dm+d historical codes ​(already live)
* ingredients for VTMs (expected in dm+d: Quarter 3 2024)
* Trade Family and Trade Family Group (expected in dm+d: Quarter 4 2024)
* removal of the 'interesting' excipient field (data has not been in dm+d extract since October 2022)

The purpose of uplifting SCCI0052 is to reflect these changes as part of the core dm+d data model and be reflected in the core dm+d extract, rather than as Supplementary Files.

We have produced a short survey to assess the impact on users and the resultant change to the core dm+d files and download.

A sample test file has been provided which reflects the proposed changes **Note: this file is not official dm+d data and has been created for test purposes only.**

**You can find all the information, including the survey and test file** [here](https://nhsengland.kahootz.com/t_c_home/viewBlogArticle?articleID=1070105&nextURL=%2Ft_c_home%2FviewBlog%3Fblogid%3D50136)

Please submit your response by **5pm on Friday 21 June 2024.**

If you have any issues completing the survey or would like to discuss this work further, please contact nhsdigital.ukmeds@nhs.net

**SNOMED International Proposal to Increase Description Length Limit**

SNOMED International are proposing to increase the maximum length of Fully Specified Name and Synonym descriptions from 255 to 4096 characters.

As the UK Member’s National Release Centre, NHS England is collating feedback from SNOMED CT users in the UK on behalf of SNOMED International.

For further information about the proposal and to submit your feedback, go to the [Delen news article](https://nhsengland.kahootz.com/t_c_home/viewBlogArticle?articleID=1061497&nextURL=%2Ft_c_home%2FviewBlog%3Fblogid%3D50136)

The deadline for survey responses is **5pm on Wednesday, 31 July 2024**.

This proposal will not impact the dm+d, we are not planning to make any changes to the dm+d as a result of this proposal from SNOMED International.

**Addition of dm+d links to BNF codes going live in Terminology Server**

The addition of dm+d links to BNF codes within the Terminology Server are now live. This means the same BNF links from dm+d will be available in TRUD and the Terminology Server at the same time moving forwards

**SNOMED International consultation on the inactivation of Role Groupers in Substance and Medicinal Product Hierarchies**

Following the [consultation](https://nhsengland.kahootz.com/t_c_home/viewBlogArticle?articleID=994809&nextURL=%2Ft_c_home%2FviewBlog%3Fblogid%3D50136) SNOMED International ran up to the end of January regarding the ‘Inactivation of Role Groupers in Substance and Medicinal Product Hierarchies’, their Content Team has released their ‘Universal Summary of all feedback received’ document which can be found [here](https://nhsengland.kahootz.com/t_c_home/viewBlogArticle?articleID=1047481&nextURL=%2Ft_c_home%2FviewBlog%3Fblogid%3D50136).

Under the ‘**Resolution and Next Steps**’ section of the document:

* The Substance role groupers will remain in situ with no change.
* A disclaimer will be added to the SNOMED CT Editorial Guide related to known issues with use of Substance role groupers including potential incorrect classification.
* A Briefing Note will follow regarding the inactivation of Medicinal Product therapeutic role groupers

The next step is for NHS England to circulate the Briefing Note regarding the ‘inactivation of Medicinal Product therapeutic role groupers’ and communicate next steps relating to this.

If you have any questions, please email information.standards@nhs.net

**Addition of 'Ingredients for VTMs' in dm+d (XML) release files and SNOMED CT UK Drug Extension**

The addition of ingredients for Virtual Therapeutic Moiety (VTMs) is planned to go-live in August and the exact date will be confirmed nearer the time. Additional information about the change is available on our [webpage](https://digital.nhs.uk/services/terminology-and-classifications/uk-medicines-terminology-futures/changes-to-digital-terminologies/addition-of-ingredients-for-vtms-in-dm-d-xml-release-files-and-snomed-ct-uk-drug-extension).

If you have any specific queries relating to the dm+d and SNOMED CT UK Drug Extension changes, please contact nhsdigital.ukmeds@nhs.net

**DHSC require these concepts to be made available and visible (similar to licensed medicines) in prescribing and dispensing systems for the time being.**

|  |
| --- |
| **Specials/Imports added at request of DHSC to mitigate shortages in the supply chain** |
| **AMP Name** | **AMP SNOMED Code** | **Import/Special** | **dm+d extract date** |
| Desmopressin 150micrograms/dose nasal spray | 38955011000001100 | Imported  |  14/09/2020 |
| Desmopressin 150micrograms/dose nasal spray | 38996011000001101 | Special Order |  21/09/2020 |
| Capsaicin 0.025% cream | 41539411000001105 | Imported |  27/03/2023 |
| Capsaicin 0.075% cream | 41540711000001105 | Imported |  27/03/2023 |
| Pethidine 50mg tablets | 42161611000001107 | Imported (United States) |  14/08/2023 |
| Permethrin 5% cream | 42243511000001101 | Imported |  18/09/2023 |
| Vyvanse 40mg capsules | 42409611000001105 | Imported |  13/11/2023 |
| Lisdexamfetamine 40mg capsules | 42415411000001107 | Imported |  20/11/2023 |
| Griseofulvin 125mg tablets | 42441511000001104 | Imported (United States) |  27/11/2023 |
| Griseofulvin 500mg tablets | 42441811000001101 | Imported (United States) |  27/11/2023 |
| Dicycloverine 10mg/5ml oral solution | 42491411000001108 | Imported (United States) |  11/12/2023 |
| Hydrogen peroxide 3% solution  | 42510811000001109 | Imported |  18/12/2023 |
| Lisdexamfetamine 60mg capsules | 42640611000001108 | Imported |  19/02/2024 |
| Methadone 5mg tablets | 42641811000001104 | Imported |  19/02/2024 |
| Salbutamol 2.5mg/2.5ml nebuliser liquid unit dose vials  | 42642011000001102 | Imported |  19/02/2024 |
| Mesalazine 400mg gastro-resistant tablets | 42836111000001108 | Imported |  20/05/2024 |
| Guanfacine 2mg modified-release tablets | 42836611000001100 | Imported |  20/05/2024 |
| Guanfacine 3mg modified-release tablets | 42836911000001106 | Imported |  20/05/2024 |

**Invalidations**

None

**Advance Notice of Invalidations**

The following concepts will be invalidated mid-June. The pack sizes were authored erroneously. Pack sizes for such concepts should not be based on bottle sizes.

The dm+d Content Committee has decided that in this scenario, the most pragmatic decision is to author pack sizes based on the volumes of water to be added for reconstitution.

|  |  |
| --- | --- |
| **Concept to be made Invalid** | **Replacement concepts** |
| **VMP**Dasatinib 10mg/ml oral suspension (VMP not to be made invalid) | **VMP**N/A |
| **VMP SNOMED ID**37223211000001104 | **VMP SNOMED ID**N/A |
| **VMPP**99ml | **VMPP**90ml |
| **VMPP SNOMED ID**37221811000001102 | **VMPP SNOMED ID**42759611000001106 |
| **AMP**Sprycel 10mg/ml oral suspension (Imported (Germany)) (AMP not to be made invalid) | **AMP**N/A |
| **AMP SNOMED ID**37221911000001107 | **AMP SNOMED ID**N/A |
| **AMPP**99ml | **AMPP**90ml |
| **AMPP SNOMED ID**37222011000001100 | **AMPP SNOMED ID**42759711000001102 |

|  |  |
| --- | --- |
| **Concept to be made Invalid** | **Replacement concepts** |
| **VMP**Mycophenolate mofetil 1g/5ml oral suspension sugar free(VMP not to be made invalid) | **VMP**N/A |
| **VMP SNOMED ID**4897811000001103 | **VMP SNOMED ID**N/A |
| **VMPP**175ml | **VMPP**160ml |
| **VMPP SNOMED ID**4881111000001102  | **VMPP SNOMED ID**42760011000001103 |
| **AMP**Cellcept 1g/5ml oral suspension (Roche Products Ltd) (AMP not to be made invalid) | **AMP**N/A |
| **AMP SNOMED ID**4881311000001100 | **AMP SNOMED ID**N/A |
| **AMPP**175ml | **AMPP**160ml |
| **AMPP SNOMED ID**4881411000001107 | **AMPP SNOMED ID**42760111000001102 |

|  |  |
| --- | --- |
| **Concept to be made Invalid** | **Replacement concepts** |
| **VMP**Oseltamivir 6mg/ml oral suspension sugar free(VMP not to be made invalid) | **VMP**N/A |
| **VMP SNOMED ID**21525811000001108 | **VMP SNOMED ID**N/A |
| **VMPP**65ml | **VMPP**50ml |
| **VMPP SNOMED ID**21525011000001102 | **VMPP SNOMED ID**42760811000001109 |
| **AMP**Tamiflu 6mg/ml oral suspension (Roche Products Ltd) (AMP not to be made invalid) | **AMP**N/A |
| **AMP SNOMED ID**21525111000001101 | **AMP SNOMED ID**N/A |
| **AMPP**65ml | **AMPP**50ml |
| **AMPP SNOMED ID**21525211000001107 | **AMPP SNOMED ID**42760911000001104 |

|  |  |
| --- | --- |
| **Concept to be made Invalid** | **Replacement concepts** |
| **VMP**Valganciclovir 50mg/ml oral solution sugar free (VMP not to be made invalid) | **VMP**N/A |
| **VMP SNOMED ID**15362311000001103 | **VMP SNOMED ID**N/A |
| **VMPP**100ml | **VMPP**88ml |
| **VMPP SNOMED ID**15354811000001108 | **VMPP SNOMED ID**42760411000001107 |
| **AMP**Valcyte 50mg/ml oral solution (Neon Healthcare Ltd) (AMP not to be made invalid) | **AMP**N/A |
| **AMP SNOMED ID**15354911000001103 | **AMP SNOMED ID**N/A |
| **AMPP**100ml | **AMPP**88ml |
| **AMPP SNOMED ID**15355011000001103 | **AMPP SNOMED ID**42760511000001106 |

|  |  |
| --- | --- |
| **Concept to be made Invalid** | **Replacement concepts** |
| **VMP**Sildenafil 10mg/ml oral suspension sugar free (VMP not to be made invalid) | **VMP**N/A |
| **VMP SNOMED ID**21705011000001109 | **VMP SNOMED ID**N/A |
| **VMPP**112ml | **VMPP**90ml |
| **VMPP SNOMED ID**21700111000001102 | **VMPP SNOMED ID**42760611000001105 |
| **AMP**Revatio 10mg/ml oral suspension (Viatris UK Healthcare Ltd) (AMP not to be made invalid) | **AMP**N/A |
| **AMP SNOMED ID**21700211000001108 | **AMP SNOMED ID**N/A |
| **AMPP**112ml | **AMPP**90ml |
| **AMPP SNOMED ID**21700311000001100 | **AMPP SNOMED ID**42760711000001101 |

|  |  |
| --- | --- |
| **Concept to be made Invalid** | **Replacement concepts** |
| **VMP**Voriconazole 200mg/5ml oral suspension (VMP not to be made invalid) | **VMP**N/A |
| **VMP SNOMED ID**41772711000001109 | **VMP SNOMED ID**N/A |
| **VMPP**75ml | **VMPP**70ml |
| **VMPP SNOMED ID**7961111000001103 | **VMPP SNOMED ID**42760211000001108 |
| **AMP**VFEND 40mg/ml oral suspension (Pfizer Ltd) (AMP not to be made invalid) | **AMP**N/A |
| **AMP SNOMED ID**7961211000001109 | **AMP SNOMED ID**N/A |
| **AMPP**75ml | **AMPP**70ml |
| **AMPP SNOMED ID**7961311000001101 | **AMPP SNOMED ID**42760311000001100 |

The following concepts will be invalidated mid-June. The pack sizes were authored erroneously.

|  |  |
| --- | --- |
| **Concept to be made Invalid** | **Replacement concepts** |
| **VMP**Clopidogrel 75mg tablets (VMP not to be made invalid) | **VMP**N/A |
| **VMP SNOMED ID**39689111000001106 | **VMP SNOMED ID**N/A |
| **VMPP**14 tablet | **VMPP**N/A |
| **VMPP SNOMED ID**40314711000001101 | **VMPP SNOMED ID**N/A |
| **AMP**Clopidogrel 75mg tablets (Medreich Plc) (AMP not to be made invalid) | **AMP**N/A |
| **AMP SNOMED ID**40314811000001109 | **AMP SNOMED ID**N/A |
| **AMPP**14 tablet | **AMPP**N/A |
| **AMPP SNOMED ID**40314911000001104 | **AMPP SNOMED ID**N/A |

|  |  |
| --- | --- |
| **Concept to be made Invalid** | **Replacement concepts** |
| **VMP**Ivabradine 5mg tablets (VMP not to be made invalid) | **VMP**N/A |
| **VMP SNOMED ID**9831411000001101 | **VMP SNOMED ID**N/A |
| **VMPP**28 tablet | **VMPP**N/A |
| **VMPP SNOMED ID**41728811000001103 | **VMPP SNOMED ID**N/A |
| **AMP**Ivabradine 5mg tablets (Medreich Plc) (AMP not to be made invalid) | **AMP**N/A |
| **AMP SNOMED ID**41728711000001106 | **AMP SNOMED ID**N/A |
| **AMPP**28 tablet | **AMPP**N/A |
| **AMPP SNOMED ID**41729011000001104 | **AMPP SNOMED ID**N/A |

|  |  |
| --- | --- |
| **Concept to be made Invalid** | **Replacement concepts** |
| **VMP**Paroxetine 10mg tablets (VMP not to be made invalid) | **VMP**N/A |
| **VMP SNOMED ID**39701911000001102 | **VMP SNOMED ID**N/A |
| **VMPP**14 tablet | **VMPP**N/A |
| **VMPP SNOMED ID**42446511000001108 | **VMPP SNOMED ID**N/A |
| **AMP**Paroxetine 10mg tablets (Medreich Plc) (AMP not to be made invalid) | **AMP**N/A |
| **AMP SNOMED ID**35851411000001109 | **AMP SNOMED ID**N/A |
| **AMPP**14 tablet | **AMPP**N/A |
| **AMPP SNOMED ID**42446711000001103 | **AMPP SNOMED ID**N/A |

The following concept will be invalidated mid-June. This product was authored erroneously.

|  |  |
| --- | --- |
| **Concept to be made Invalid** | **Replacement concepts** |
| **VMP**Ivabradine 7.5mg tablets (VMP not to be made invalid) | **VMP**N/A |
| **VMP SNOMED ID**9831511000001102 | **VMP SNOMED ID**N/A |
| **VMPP**28 tablet | **VMPP**N/A |
| **VMPP SNOMED ID**41729311000001101 | **VMPP SNOMED ID**N/A |
| **VMPP**56 tablet (VMPP not to be made invalid) | **VMPP**N/A |
| **VMPP SNOMED ID**9830111000001100 | **VMPP SNOMED ID**N/A |
| **AMP**Ivabradine 7.5mg tablets (Medreich Plc) | **AMP**N/A |
| **AMP SNOMED ID**41729111000001103 | **AMP SNOMED ID**N/A |
| **AMPP**28 tablet | **AMPP**N/A |
| **AMPP SNOMED ID**41729411000001108 | **AMPP SNOMED ID**N/A |
| **AMPP**56 tablet | **AMPP**N/A |
| **AMPP SNOMED ID**41729211000001109 | **AMPP SNOMED ID**N/A |

The following concept will be invalidated mid-July. The pharma company has admitted an error at the stage of informing the NHSBSA about this product and hence the necessary authoring updates are required

|  |  |
| --- | --- |
| **Concept to be made Invalid** | **Replacement concepts** |
| **VMP**Donepezil 10mg orodispersible tablets (not being invalidated) | **VMP**Donepezil 10mg orodispersible tablets sugar free |
| **VMP SNOMED ID**20346711000001101 | **VMP SNOMED ID**11140311000001101 |
| **VMPP**28 (not being invalidated) | **VMPP**28 |
| **VMPP SNOMED ID**20346411000001107 | **VMPP SNOMED ID**11133511000001100 |
| **AMP**Donepezil 10mg orodispersible tablets (Macleods Pharma UK Ltd) | **AMP**Donepezil 10mg orodispersible tablets sugar free (Macleods Pharma UK Ltd) |
| **AMP SNOMED ID**42478611000001109 | **AMP SNOMED ID**42893011000001108 |
| **AMPP**28 tablet | **AMPP**28 tablet |
| **AMPP SNOMED ID**42479011000001107 | **AMPP SNOMED ID**42893111000001109 |

The following concepts will be invalidated mid-July. The pharma company has retrospectively decided that these concepts should more accurately be described as sugar free.

|  |  |
| --- | --- |
| **Concept to be made Invalid** | **Replacement concepts** |
| **VMP**Fentanyl 133microgram sublingual tablets | **VMP**Fentanyl 133microgram sublingual tablets sugar free |
| **VMP SNOMED ID**42288411000001101 | **VMP SNOMED ID**24446611000001102 |
| **VMPP**4 tablet | **VMPP**4 tablet |
| **VMPP SNOMED ID**42282411000001103 | **VMPP SNOMED ID**42889711000001109 |
| **AMP**Iremia 133microgram sublingual tablets (Kent Pharma (UK) Ltd) | **AMP**Iremia 133microgram sublingual tablets (Kent Pharma (UK) Ltd) |
| **AMP SNOMED ID**42282511000001104 | **AMP SNOMED ID**42890011000001103 |
| **AMPP**4 tablet | **AMPP**4 tablet |
| **AMPP SNOMED ID**42282611000001100 | **AMPP SNOMED ID**42890111000001102 |

|  |  |
| --- | --- |
| **Concept to be made Invalid** | **Replacement concepts** |
| **VMP**Fentanyl 267microgram sublingual tablets | **VMP**Fentanyl 267microgram sublingual tablets sugar free |
| **VMP SNOMED ID**42288311000001108 | **VMP SNOMED ID**24446711000001106 |
| **VMPP**4 tablet | **VMPP**4 tablet |
| **VMPP SNOMED ID**42282711000001109 | **VMPP SNOMED ID**42890711000001101 |
| **AMP**Iremia 267microgram sublingual tablets (Kent Pharma (UK) Ltd) | **AMP**Iremia 267microgram sublingual tablets (Kent Pharma (UK) Ltd) |
| **AMP SNOMED ID**42282811000001101 | **AMP SNOMED ID**42890811000001109 |
| **AMPP**4 tablet | **AMPP**4 tablet |
| **AMPP SNOMED ID**42282911000001106 | **AMPP SNOMED ID**42890911000001104 |

|  |  |
| --- | --- |
| **Concept to be made Invalid** | **Replacement concepts** |
| **VMP**Fentanyl 400microgram sublingual tablets | **VMP**Fentanyl 400microgram sublingual tablets sugar free |
| **VMP SNOMED ID**42288211000001100  | **VMP SNOMED ID**14952211000001101  |
| **VMPP**4 tablet | **VMPP**4 tablet |
| **VMPP SNOMED ID**42283011000001103  | **VMPP SNOMED ID**42891011000001107  |
| **AMP**Iremia 400microgram sublingual tablets (Kent Pharma (UK) Ltd) | **AMP**Iremia 400microgram sublingual tablets (Kent Pharma (UK) Ltd) |
| **AMP SNOMED ID**42283111000001102  | **AMP SNOMED ID**42891211000001102  |
| **AMPP**4 tablet | **AMPP**4 tablet |
| **AMPP SNOMED ID**42283211000001108  | **AMPP SNOMED ID**42891311000001105  |

|  |  |
| --- | --- |
| **Concept to be made Invalid** | **Replacement concepts** |
| **VMP**Fentanyl 533microgram sublingual tablets | **VMP**Fentanyl 533microgram sublingual tablets sugar free |
| **VMP SNOMED ID**42288111000001106  | **VMP SNOMED ID**24446811000001103  |
| **VMPP**4 tablet | **VMPP**4 tablet |
| **VMPP SNOMED ID**42283311000001100  | **VMPP SNOMED ID**42891811000001101  |
| **AMP**Iremia 533microgram sublingual tablets (Kent Pharma (UK) Ltd) | **AMP**Iremia 533microgram sublingual tablets (Kent Pharma (UK) Ltd) |
| **AMP SNOMED ID**42283411000001107  | **AMP SNOMED ID**42892011000001104  |
| **AMPP**4 tablet | **AMPP**4 tablet |
| **AMPP SNOMED ID**42283511000001106  | **AMPP SNOMED ID**42892111000001103  |

|  |  |
| --- | --- |
| **Concept to be made Invalid** | **Replacement concepts** |
| **VMP**Fentanyl 800microgram sublingual tablets | **VMP**Fentanyl 800microgram sublingual tablets sugar free |
| **VMP SNOMED ID**42287911000001108  | **VMP SNOMED ID**14952411000001102  |
| **VMPP**4 tablet | **VMPP**4 tablet |
| **VMPP SNOMED ID**42283911000001104  | **VMPP SNOMED ID**42892311000001101  |
| **AMP**Iremia 800microgram sublingual tablets (Kent Pharma (UK) Ltd) | **AMP**Iremia 800microgram sublingual tablets (Kent Pharma (UK) Ltd) |
| **AMP SNOMED ID**42284011000001101  | **AMP SNOMED ID**42892611000001106  |
| **AMPP**4 tablet | **AMPP**4 tablet |
| **AMPP SNOMED ID**42284111000001100  | **AMPP SNOMED ID**42892711000001102  |

|  |  |
| --- | --- |
| **Concept to be made Invalid** | **Replacement concepts** |
| **VMP**Fentanyl 67microgram sublingual tablets | **VMP**Fentanyl 67microgram sublingual tablets sugar free |
| **VMP SNOMED ID**42288011000001105  | **VMP SNOMED ID**42894311000001108 |
| **VMPP**4 tablet | **VMPP**4 tablet |
| **VMPP SNOMED ID**42283611000001105  | **VMPP SNOMED ID**42893911000001107  |
| **AMP**Iremia 67microgram sublingual tablets (Kent Pharma (UK) Ltd) | **AMP**Iremia 67microgram sublingual tablets (Kent Pharma (UK) Ltd) |
| **AMP SNOMED ID**42283711000001101  | **AMP SNOMED ID**42894011000001105  |
| **AMPP**4 tablet | **AMPP**4 tablet |
| **AMPP SNOMED ID**42283811000001109  | **AMPP SNOMED ID**42894111000001106  |

dm+d Authoring Team